Ustekinumab Approved by NICE for Moderate to Severe Plaque Psoriasis
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Ustekinumab Approved by NICE for Moderate to Severe Plaque Psoriasis

NEW YORK -- September 23, 2009 -- The National Institute for Health and Clinical Excellence (NICE) has approved ustekinumab (Stelara) as a treatment option for adults with moderate to severe plaque psoriasis who have not respond to, or have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate, and psoralen plus ultraviolet A light (PUVA).

In clinical studies, treatment with ustekinumab demonstrated a significant, visible improvement in patient’s psoriasis with convenient 12 weekly maintenance dosing. This has the potential to give patients with psoriasis greater freedom to live their lives with a significantly reduced burden of disease and without the inconvenience of frequent injections.

“Two-thirds of patients taking [ustekinumab] in placebo-controlled trials saw a significant, visible improvement in their psoriasis in as little as 12 weeks,” said Christopher Griffiths, MD, Department of Dermatology, University of Manchester, Manchester, United Kingdom.

“This is reflective of what I have seen in clinical practice, with patients experiencing considerable improvements in skin clearance with the added benefit of a convenient dosing regimen.”

SOURCE: Johnson&Johnson

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities